000181689 001__ 181689
000181689 005__ 20240229145654.0
000181689 0247_ $$2doi$$a10.1158/1055-9965.EPI-22-0681
000181689 0247_ $$2pmid$$apmid:36099423
000181689 0247_ $$2ISSN$$a1055-9965
000181689 0247_ $$2ISSN$$a1538-7755
000181689 0247_ $$2altmetric$$aaltmetric:135899741
000181689 037__ $$aDKFZ-2022-02165
000181689 041__ $$aEnglish
000181689 082__ $$a610
000181689 1001_ $$00000-0003-4084-8340$$aHimbert, Caroline$$b0
000181689 245__ $$aAssociations of individual and combined physical activity and body mass index groups with pro-inflammatory biomarkers among colorectal cancer patients.
000181689 260__ $$aPhiladelphia, Pa.$$bAACR$$c2022
000181689 3367_ $$2DRIVER$$aarticle
000181689 3367_ $$2DataCite$$aOutput Types/Journal article
000181689 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1670330104_13268
000181689 3367_ $$2BibTeX$$aARTICLE
000181689 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181689 3367_ $$00$$2EndNote$$aJournal Article
000181689 500__ $$a2022 Dec 5;31(12):2148-2156
000181689 520__ $$aPhysical activity and obesity are well-established factors of colorectal cancer (CRC) risk and prognosis. Here, we investigate associations of individual and combined physical activity and BMI groups with pro-inflammatory biomarkers in CRC patients.Self-reported physical activity levels were classified as 'active' (≥8.75 MET-hrs/wk) vs. 'inactive' (<8.75 MET-hrs/wk) in n=579 stage I-IV CRC patients enrolled in the ColoCare Study. BMI [normal weight (≥18.5-<25kg/m2), overweight (≥25-<30kg/m2), and obese (≥30kg/m2)] was abstracted from medical records. Patients were classified into four combinations of physical activity levels and BMI. Biomarkers (CRP, SAA, IL-6, IL-8, and TNF-α) in pre-surgery serum samples were measured using Meso-Scale-Discovery platform. Regression models were used to compute relative percent differences in biomarker levels by physical activity and BMI groups.'Inactive' patients had non-statistically significant higher IL-6 levels compared to 'active' patients (+36%, p=0.10). 'Obese' patients had 88% and 17% higher CRP and TNF-α levels compared to 'normal weight' patients (p=0.03 and 0.02, respectively). Highest CRP levels were observed among 'overweight or obese/inactive' compared to 'normal weight/active' patients (p=0.03).We provide evidence of associations between individual and combined physical activity and BMI groups with pro-inflammatory biomarkers. While BMI was identified as the key driver of inflammation, biomarker levels were higher among 'inactive' patients across BMI groups.This is the largest study in CRC patients investigating associations of energy balance components with inflammatory biomarkers. Our results suggest that physical activity may reduce obesity-induced inflammation in CRC patients and support the design of randomized controlled trials testing this hypothesis.
000181689 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000181689 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181689 7001_ $$00000-0003-1772-8332$$aWarby, Christy A$$b1
000181689 7001_ $$aGigic, Biljana$$b2
000181689 7001_ $$aOse, Jennifer$$b3
000181689 7001_ $$00000-0001-5147-8432$$aLin, Tengda$$b4
000181689 7001_ $$00000-0001-7167-174X$$aViskochil, Richard$$b5
000181689 7001_ $$00000-0003-3645-3960$$aPeoples, Anita R$$b6
000181689 7001_ $$00000-0002-9676-7702$$aAshworth, Anjelica$$b7
000181689 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b8$$udkfz
000181689 7001_ $$00000-0003-2497-4961$$aScaife, Courtney L$$b9
000181689 7001_ $$00000-0002-5461-4716$$aCohan, Jessica N$$b10
000181689 7001_ $$00000-0002-9408-3139$$aJedrzkiewicz, Jolanta$$b11
000181689 7001_ $$aSchirmacher, Peter$$b12
000181689 7001_ $$00000-0002-0129-7809$$aGrady, William M$$b13
000181689 7001_ $$00000-0002-6207-9856$$aCohen, Stacey A$$b14
000181689 7001_ $$00000-0003-4872-1061$$aKrane, Mukta$$b15
000181689 7001_ $$00000-0001-8040-3341$$aFigueiredo, Jane C$$b16
000181689 7001_ $$00000-0003-1079-2606$$aToriola, Adetunji T$$b17
000181689 7001_ $$00000-0003-1779-2510$$aSiegel, Erin M$$b18
000181689 7001_ $$00000-0002-5670-423X$$aShibata, David$$b19
000181689 7001_ $$00000-0002-7158-9874$$aRound, June L$$b20
000181689 7001_ $$00000-0002-8605-2631$$aHuang, Lyen C$$b21
000181689 7001_ $$00000-0003-1543-0743$$aLi, Christopher I$$b22
000181689 7001_ $$aSchneider, Martin$$b23
000181689 7001_ $$00000-0003-1469-2186$$aUlrich, Alexis$$b24
000181689 7001_ $$00000-0003-0292-6168$$aHardikar, Sheetal$$b25
000181689 7001_ $$00000-0001-7641-059X$$aUlrich, Cornelia M$$b26
000181689 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-22-0681$$gp. EPI-22-0681$$n12$$p2148-2156$$tCancer epidemiology, biomarkers & prevention$$v31$$x1055-9965$$y2022
000181689 909CO $$ooai:inrepo02.dkfz.de:181689$$pVDB
000181689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000181689 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000181689 9141_ $$y2022
000181689 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000181689 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000181689 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000181689 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2021$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000181689 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-10
000181689 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000181689 980__ $$ajournal
000181689 980__ $$aVDB
000181689 980__ $$aI:(DE-He78)C120-20160331
000181689 980__ $$aUNRESTRICTED